Northern Trust’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-114,434
| Closed | -$253K | – | 4552 |
|
|
2023
Q2 | $253K | Buy |
114,434
+1,772
| +2% | +$3.67K | ﹤0.01% | 3734 |
|
|
2023
Q1 | $286K | Buy |
112,662
+1,994
| +2% | +$3.94K | ﹤0.01% | 3690 |
|
|
2022
Q4 | $207K | Sell |
110,668
-575
| -0.5% | -$1.43K | ﹤0.01% | 3857 |
|
|
2022
Q3 | $286K | Buy |
111,243
+3,526
| +3% | +$8.77K | ﹤0.01% | 3702 |
|
|
2022
Q2 | $208K | Sell |
107,717
-341,620
| -76% | -$745K | ﹤0.01% | 3904 |
|
|
2022
Q1 | $1.33M | Sell |
449,337
-17,460
| -4% | -$65.7K | ﹤0.01% | 3290 |
|
|
2021
Q4 | $2.1M | Sell |
466,797
-74
| -0% | -$351 | ﹤0.01% | 3197 |
|
|
2021
Q3 | $2.27M | Sell |
466,871
-14,191
| -3% | -$78.2K | ﹤0.01% | 3222 |
|
|
2021
Q2 | $3.28M | Sell |
481,062
-5,228
| -1% | -$42.3K | ﹤0.01% | 3099 |
|
|
2021
Q1 | $3.43M | Sell |
486,290
-46,662
| -9% | -$336K | ﹤0.01% | 2975 |
|
|
2020
Q4 | $3.34M | Sell |
532,952
-5,985
| -1% | -$35.2K | ﹤0.01% | 2909 |
|
|
2020
Q3 | $2.92M | Sell |
538,937
-19,441
| -3% | -$96.3K | ﹤0.01% | 2859 |
|
|
2020
Q2 | $2.91M | Buy |
558,378
+134,236
| +32% | +$596K | ﹤0.01% | 2826 |
|
|
2020
Q1 | $1.34M | Buy |
424,142
+25,342
| +6% | +$93.5K | ﹤0.01% | 3068 |
|
|
2019
Q4 | $1.61M | Sell |
398,800
-27,589
| -6% | -$95.7K | ﹤0.01% | 3232 |
|
|
2019
Q3 | $1.84M | Buy |
426,389
+12,025
| +3% | +$48.1K | ﹤0.01% | 3142 |
|
|
2019
Q2 | $1.65M | Buy |
414,364
+4,517
| +1% | +$21.5K | ﹤0.01% | 3164 |
|
|
2019
Q1 | $2.2M | Sell |
409,847
-3,069
| -0.7% | -$19.8K | ﹤0.01% | 3021 |
|
|
2018
Q4 | $2.12M | Sell |
412,916
-19,174
| -4% | -$146K | ﹤0.01% | 3015 |
|
|
2018
Q3 | $4.19M | Buy |
432,090
+23,244
| +6% | +$234K | ﹤0.01% | 2790 |
|
|
2018
Q2 | $4.17M | Buy |
408,846
+47,440
| +13% | +$537K | ﹤0.01% | 2779 |
|
|
2018
Q1 | $4.7M | Buy |
361,406
+41,608
| +13% | +$619K | ﹤0.01% | 2626 |
|
|
2017
Q4 | $5.72M | Sell |
319,798
-7,819
| -2% | -$163K | ﹤0.01% | 2529 |
|
|
2017
Q3 | $8.22M | Sell |
327,617
-2,076
| -0.6% | -$48.3K | ﹤0.01% | 2316 |
|
|
2017
Q2 | $7.95M | Buy |
329,693
+67,794
| +26% | +$1.5M | ﹤0.01% | 2318 |
|
|
2017
Q1 | $5.04M | Buy |
261,899
+16,505
| +7% | +$260K | ﹤0.01% | 2546 |
|
|
2016
Q4 | $3.78M | Buy |
245,394
+18,813
| +8% | +$244K | ﹤0.01% | 2731 |
|
|
2016
Q3 | $2.95M | Buy |
226,581
+53,602
| +31% | +$711K | ﹤0.01% | 2849 |
|
|
2016
Q2 | $2.41M | Buy |
172,979
+35,108
| +25% | +$517K | ﹤0.01% | 2925 |
|
|
2016
Q1 | $2.09M | Buy |
137,871
+3,193
| +2% | +$48.8K | ﹤0.01% | 2956 |
|
|
2015
Q4 | $2.56M | Buy |
134,678
+9,756
| +8% | +$186K | ﹤0.01% | 2900 |
|
|
2015
Q3 | $2.37M | Buy |
124,922
+106,096
| +564% | +$2.64M | ﹤0.01% | 2941 |
|
|
2015
Q2 | $486K | Buy |
+18,826
| New | +$534K | ﹤0.01% | 3570 |
|
|
2014
Q4 | – | Sell |
-2,313
| Closed | -$56K | – | 4300 |
|
|
2014
Q3 | $56K | Buy |
2,313
+21
| +0.9% | +$548 | ﹤0.01% | 4127 |
|
|
2014
Q2 | $54K | Sell |
2,292
-6
| -0.3% | -$196 | ﹤0.01% | 4102 |
|
|
2014
Q1 | $85K | Hold |
2,298
| – | – | ﹤0.01% | 3977 |
|
|
2013
Q4 | $92K | Sell |
2,298
-8
| -0.3% | -$340 | ﹤0.01% | 3879 |
|
|
2013
Q3 | $88K | Sell |
2,306
-8,274
| -78% | -$296K | ﹤0.01% | 3830 |
|
|
2013
Q2 | $384K | Buy |
+10,580
| New | +$453K | ﹤0.01% | 3507 |
|
Northern Trust's PRTK Position: Q3 2023 in Review
Northern Trust sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 114,434 shares — an estimated $253K sold.
Northern Trust first reported a position in PRTK in Q2 2013 and held it in 39 quarters. The position peaked at $8.22M in Q3 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Northern Trust reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Northern Trust sold 114,434 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $253K.
- Northern Trust first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 39 quarters.
- Northern Trust's Paratek Pharmaceuticals, Inc. position peaked at $8.22M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.